Physician profile
Igor Chaplik
NPI 1952410789
$11,901.09
in general payments reported to CMS, 2019-2025
44 companies · $2,235 in 2025
The $2,235 reported for 2025 was more than what 78% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,585 · 2020: $1,087 · 2021: $1,559 · 2022: $1,691 · 2023: $1,627 · 2024: $2,117 · 2025: $2,235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,903 · Education: $75.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,903.13 |
| Education | $75.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,823.62 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $1,692.10 | 2020-2025 | Tremfya, Stelara, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $1,205.52 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $777.83 | 2019-2025 | Ilumya |
| Ucb, INC. | $696.57 | 2021-2025 | Bimzelx, Cimzia |
| Biofrontera INC. | $625.86 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Lilly USA, LLC | $553.90 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $533.36 | 2019-2025 | |
| Amgen INC. | $468.74 | 2019-2025 | Otezla, Otezla |
| Genzyme Corporation | $438.10 | 2019-2025 | |
| Galderma Laboratories, L.P. | $408.25 | 2019-2025 | Nemluvio |
| Regeneron Healthcare Solutions, INC. | $330.06 | 2019-2025 | Dupixent |
| Incyte Corporation | $269.40 | 2022-2025 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $226.87 | 2022-2025 | Spevigo |
| Organogenesis INC. | $220.26 | 2021-2024 |
Show all 39 companies
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Igor Chaplik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.